Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Korean Circ J. 2012 May;42(5):319-28. doi: 10.4070/kcj.2012.42.5.319. Epub 2012 May 24.

Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Author information

  • 1The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.

Abstract

BACKGROUND AND OBJECTIVES:

Non-high density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (ApoB) are markers of atherosclerotic risk and predictors of cardiovascular events. The aim of this study was to evaluate clinical impact of non-HDL-C and ApoB on clinical outcomes in metabolic syndrome (MS) patients with acute myocardial infarction (AMI) undergoing percuatneous coronary intervetion.

SUBJECTS AND METHODS:

We analyzed 470 MS patients (64.4±12.0 years, 53.6% male) with AMI who were followed-up for 12-month after percutaneous coronary intervention (PCI) from December 2005 to January 2008 in a single center. These patients were divided into 2 groups based on median values of non-HDL-C and ApoB. We studied their baseline and follow-up relation with 12-month clinical outcomes, all-cause death and major adverse cardiac events (MACE).

RESULTS:

Mean values of baseline non-HDL-C and ApoB were 141.2±43.1 mg/dL and 99.3±29.0 mg/dL respectively. During 12-month follow-up 32 MACE (6.8%) and 12 deaths (2.5%) occurred. We observed significant correlation between non-HDL-C and ApoB. Twelve-month MACE and all-cause death after PCI showed no significant relation as non-HDL-C or ApoB levels increased. Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes. Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.

CONCLUSION:

There was no significant association between higher non-HDL-C or ApoB and 12-month clinical outcomes in MS patients with AMI undergoing PCI. ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

KEYWORDS:

Apolipoproteins B; Cholesterol; Metabolic syndrome; Myocardial infarction

PMID:
22701134
[PubMed]
PMCID:
PMC3369963
Free PMC Article

Images from this publication.See all images (3)Free text

Fig. 1
Fig. 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for The Korean Society of Cardiology Icon for PubMed Central
    Loading ...
    Write to the Help Desk